Association between military service and Alzheimer's disease neuropathology at autopsy-Reference-Cited by-同舟云学术

Association between military service and Alzheimer's disease neuropathology at autopsy

Published:2023-11-15 Issue: Volume: Page:
ISSN:1552-5260
Container-title:Alzheimer's & Dementia
language:en
Short-container-title:Alzheimer's & Dementia

Author:

Powell W. Ryan¹²,Vilen Leigha¹,Zuelsdorff Megan³⁴,Goutman Stephen A.⁵,Salamat Shahriar⁶⁷,Rissman Robert A.⁸⁹,Bendlin Barbara B.¹²³¹⁰,Kind Amy J. H.¹²³

Affiliation:

1. Center for Health Disparities Research University of Wisconsin School of Medicine and Public Health Madison Wisconsin USA

2. Department of Medicine Geriatrics Division University of Wisconsin School of Medicine and Public Health Madison Wisconsin USA

3. Wisconsin Alzheimer's Disease Research Center University of Wisconsin School of Medicine and Public Health Madison Wisconsin USA

4. University of Wisconsin School of Nursing Madison Wisconsin USA

5. Department of Neurology University of Michigan Ann Arbor Michigan USA

6. Department of Neurological Surgery University of Wisconsin School of Medicine and Public Health Madison Wisconsin USA

7. Department of Pathology and Laboratory Medicine University of Wisconsin School of Medicine and Public Health Madison Wisconsin USA

8. Department of Physiology and Neuroscience Alzheimer's Therapeutic Research Institute Keck School of Medicine of the University of Southern California San Diego California USA

9. VA San Diego Healthcare System La Jolla California USA

10. Wisconsin Alzheimer's Institute University of Wisconsin School of Medicine and Public Health Madison Wisconsin USA

Abstract

AbstractINTRODUCTIONAnti‐amyloid therapies are at the forefront of efforts to treat Alzheimer's disease (AD). Identifying amyloid risk factors may aid screening and intervention strategies. While veterans face increased exposure to risk factors, whether they face a greater neuropathologic amyloid burden is not well understood.METHODSMale decedents donating to two Alzheimer's Disease Research Center (ADRC) brain banks from 1986 to 2018 with categorized neuritic plaque density and neurofibrillary tangles (n = 597) were included. Using generalized ordered logistic regression we modeled each outcome's association with military history adjusting for age and death year.RESULTSHaving served in the military (60% of sample) is associated with post mortem neuritic amyloid plaque (for each comparison of higher to lower C scores OR = 1.26; 95% confidence interval [CI] = 1.06–1.49) and tau pathology (B score OR = 1.10; 95% CI = 1.08–1.12).DISCUSSIONThis is the first study, to our knowledge, finding increased levels of verified AD neuropathology in those with military service. Targeted veteran AD therapies is a pressing need.

Publisher

Wiley

Subject

Psychiatry and Mental health,Cellular and Molecular Neuroscience,Geriatrics and Gerontology,Neurology (clinical),Developmental Neuroscience,Health Policy,Epidemiology

Reference40 articles.

1. Lecanemab: US Veterans Health Administration will cover cost of new Alzheimer’s drug

2. VA Pharmacy Benefits Management Services.Medical Advisory Panel and VISN Pharmacist Executives. Lecanemab‐irmb (LEQEMBI) Criteria for Use February 2023[Internet]. [cited 2023 May 23].https://web.archive.org/web/20230510212607/www.va.gov/formularyadvisor/DOC_PDF/CFU_Lecanemab-irmb_LEQEMBI_CFU.pdf

3. Demographic, Health, and Exposure Risks Associated With Cognitive Loss, Alzheimer's Disease and Other Dementias in US Military Veterans

4. Dementia risk and disadvantaged neighborhoods;Dintica CS;JAMA Neurol,2023

5. Exposome and Exposomics | NIOSH | CDC [Internet].2022[cited 2023 Jun 1].https://web.archive.org/web/20230523144220/www.cdc.gov/niosh/topics/exposome/default.html